Gland Pharma (BOM:543245) Ending Cash Position : ₹0 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma Ending Cash Position?

Gland Pharma's Ending Cash Position for the quarter that ended in Dec. 2024 was ₹0 Mil.

Gland Pharma's annual Ending Cash Position increased from Mar. 2022 (₹3,188 Mil) to Mar. 2023 (₹19,089 Mil) but then declined from Mar. 2023 (₹19,089 Mil) to Mar. 2024 (₹3,571 Mil).

Gland Pharma Ending Cash Position Historical Data

The historical data trend for Gland Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma Ending Cash Position Chart

Gland Pharma Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Ending Cash Position

Get a 7-Day Free Trial

1,694.97

4,924.63

3,188.20

19,088.95

3,570.88

Gland Pharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															-	-	-	-	-

Gland Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Gland Pharma's Ending Cash Position for the fiscal year that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	19088.95	+	-15518.07
	=	3,571

Gland Pharma's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0	+	0
	=	0

Gland Pharma Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Gland Pharma's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Gland Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (BOM:543245) » Definitions » Ending Cash Position

Traded in Other Exchanges

GLAND:India

Address

Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307

Website

https://www.glandpharma.com

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. The group is also involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma Headlines

No Headlines